Robert Gut - 06 Nov 2025 Form 4 Insider Report for uniQure N.V. (QURE)

Role
Director
Signature
/s/ Christian Klemt, Attorney-in-Fact
Issuer symbol
QURE
Transactions as of
06 Nov 2025
Net transactions value
-$784,492
Form type
4
Filing time
10 Nov 2025, 16:54:55 UTC
Previous filing
24 Jun 2025
Next filing
14 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gut Robert Director C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, NETHERLANDS /s/ Christian Klemt, Attorney-in-Fact 10 Nov 2025 0001716268

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QURE Ordinary Shares Options Exercise $72,389 +15,840 +28% $4.57 71,579 06 Nov 2025 Direct F1, F2
transaction QURE Ordinary Shares Sale $431,165 -15,840 -22% $27.22 55,739 06 Nov 2025 Direct F1, F3
transaction QURE Ordinary Shares Sale $425,716 -15,594 -28% $27.30 40,145 06 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QURE Stock Option (Right to Buy) Options Exercise $0 -15,840 -100% $0.000000 0 06 Nov 2025 Ordinary Shares 15,840 $4.57 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2 Adjusted to reflect (i) the sale of 1,120 shares under the Reporting Person's 10b5-1 plan on June 23, 2020, which was inadvertently omitted from the Form 4 filed on June 24, 2020, and (ii) the correction to a typographical error in the number of shares sold by the Reporting Person on June 13, 2024 reported on the Form 4 filed on June 17, 2024. The Form 4 reported the sale of 3,504 shares but should have reported the sale of 3,524 shares.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.00 to $27.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The Stock Option vested in full on June 19, 2025.